Skip to content
← All treatment topics

TREATMENT READING

Merkel Cell Carcinoma

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

39 sections
  1. Treatment Option Overview for Merkel Cell Carcinoma
  2. Surgery for the Primary Lesion
  3. Regional Lymph Node Surgery
  4. Radiation Therapy
  5. Immunotherapy
  6. Avelumab
  7. Pembrolizumab
  8. Retifanlimab
  9. Nivolumab
  10. Chemotherapy
  11. Follow-Up
  12. Treatment of Stage I and II Merkel Cell Carcinoma
  13. Treatment Options for Stage I and II Merkel Cell Carcinoma
  14. Treatment of Stage III Merkel Cell Carcinoma
  15. Treatment Options for Stage III Merkel Cell Carcinoma
  16. Treatment of Stage IV Merkel Cell Carcinoma
  17. Treatment Options for Stage IV Merkel Cell Carcinoma
  18. Treatment of Recurrent Merkel Cell Carcinoma
  19. Treatment Options for Recurrent Merkel Cell Carcinoma
  20. Local recurrence
  21. Nodal recurrence
  22. Distant recurrence
  23. Certain factors affect prognosis (chance of recovery) and treatment options.
  24. It is common for Merkel cell carcinoma to recur (come back) after it has been treated.
  25. Treatment Option Overview
  26. Key Points
  27. There are different types of treatment for people with Merkel cell carcinoma.
  28. The following types of treatment are used:
  29. Surgery
  30. Radiation therapy
  31. Chemotherapy
  32. Immunotherapy
  33. New types of treatment are being tested in clinical trials.
  34. Treatment for Merkel cell carcinoma may cause side effects.
  35. Follow-up care may be needed.
  36. Treatment of Stage I and Stage II Merkel Cell Carcinoma
  37. Treatment of Stage III Merkel Cell Carcinoma
  38. Treatment of Stage IV Merkel Cell Carcinoma
  39. Treatment of Recurrent Merkel Cell Carcinoma

Health professional

Treatment Option Overview for Merkel Cell Carcinoma

Source: Merkel Cell Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

Merkel cell carcinoma (MCC) is an uncommon tumor. Most clinical management recommendations in the literature are based on case series that describe a relatively small number of patients who were not entered on formal clinical trials, evaluated with uniform clinical staging procedures, treated with uniform treatment protocols, or provided with regular, prescribed follow-up. These reports are also confounded by potential selection bias, referral bias, and short follow-up. They are underpowered to detect modest differences in outcome.

In addition, outcomes of patients with American Joint Committee on Cancer stage I and stage II disease are often reported together. In the absence of results from clinical trials with prescribed work-up, treatments, and follow-up, most patients with MCC have been treated using institutional or practitioner preferences that consider the specifics of each case as well as patient preference.

There are two competing philosophies about the most appropriate method of treating MCC. In the first philosophy, MCC is treated like other nonmelanoma skin cancers, with an emphasis on treating local-regional disease with surgery and radiation therapy, as appropriate. In the second philosophy, MCC is treated according to its biological features. This approach makes it analogous to small cell lung cancer, which is assumed to be a systemic disease, and leads to a more routine recommendation of systematic adjuvant chemotherapy.[1]

Sources: 1

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional · Treatment Option Overview for Merkel Cell Carcinoma

Surgery for the Primary Lesion

Source: Merkel Cell Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

In a review of 18 case series, 279 of 926 patients (30.1%) developed local recurrence during follow-up, excluding those presenting with distant metastatic disease at presentation. These recurrences have been typically attributed to inadequate surgical margins or possibly a lack of adjuvant radiation therapy.[2,3]

Sources: 2 · 3

Given the propensity of MCC to recur locally (sometimes with satellite lesions and/or in-transit metastases), wide local excision to reduce the risk of local recurrence has been recommended for patients with clinical stage I or stage II disease.

Recommendations about the optimal minimum width and depth of normal tissue margin to be excised around the primary tumor differ among the various retrospective case series, but this question has not been studied systematically.[3-7][Level of evidence C2] No definitive data suggest that extremely wide margins improve overall survival (OS), although some reports suggest that wider margins appear to improve local control.[3][Level of evidence C2] Frozen-section evaluation of margins may be useful, especially when the tumor is in an anatomical site that is not amenable to wide margins.

Sources: 3 · 7 · Level of evidence C2 · 3 · Level of evidence C2

Some authors have advocated the use of Mohs micrographic surgery as a tissue-sparing technique. The relapse rate has been reported to be similar to or better than that of wide excision, but comparatively few cases have been treated in this manner and none in randomized controlled trials.[7-10][Level of evidence C2]

Sources: Mohs micrographic surgery · 7 · 10 · Level of evidence C2

Health professional · Treatment Option Overview for Merkel Cell Carcinoma

Regional Lymph Node Surgery

Source: Merkel Cell Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

In some case series, local-regional recurrence rates are high when pathological nodal staging is omitted. Surgical nodal staging in clinically negative patients has identified positive nodes in at least 25% to 35% of patients.[4,11,12][Level of evidence C2] In one retrospective series of 213 patients who underwent surgical treatment of the primary tumor and evaluation of the draining nodes, nodal positivity was found in 2 of 54 patients with small tumors (e.g., ≤1.0 cm) and 51 of 159 patients with tumors larger than 1.0 cm.[13][Level of evidence C2]

Sources: 4 · 11 · 12 · Level of evidence C2 · 13 · Level of evidence C2

The role of elective lymph node dissection (ELND) in the absence of clinically positive lymph nodes has not been studied in formal clinical trials. In small case series, ELND has been recommended for larger primary tumors, tumors with more than ten mitoses per high-power field, lymphatic or vascular invasion, and the small-cell histological subtypes.[14-16][Level of evidence C2]

Sources: 14 · 16 · Level of evidence C2

Sentinel lymph node (SLN) biopsy has been suggested as a preferred initial alternative to complete ELND for the proper staging of MCC. SLN biopsy has less morbidity than complete nodal dissection. Furthermore, for MCC sites with indeterminate lymphatic drainage, such as those on the back, SLN biopsy techniques can be used to identify the pertinent lymph node bed(s). If performed, SLN biopsy is done at the time of the wide resection when the local lymphatic channels are still intact.

Several reports have found the use of SLN biopsy techniques in MCC to be reliable and reproducible.[17-20] However, the significance of SLN positivity remains unclear.

Sources: 17 · 20

One meta-analysis of ten case series found that SLN positivity strongly predicted a high short-term risk of recurrence and that subsequent therapeutic lymph node dissection was effective in preventing short-term regional nodal recurrence.[21]

Sources: 21

Another meta-analysis included 12 retrospective case series (only partially overlapping the collection of case series in the previous meta-analysis).[12][Level of evidence C2]

Sources: 12 · Level of evidence C2

Another meta-analysis included 12 retrospective case series (only partially overlapping the collection of case series in the previous meta-analysis).[12][Level of evidence C2]

SLN biopsy detected MCC spread in one-third of patients whose tumors would have otherwise been clinically and radiologically understaged.

The recurrence rate was three times higher in patients with a positive SLN biopsy than in those with a negative SLN biopsy (P = .03).

Between 2006 and 2010, a large, retrospective, single-institutional series of 95 patients (with a total of 97 primary tumors) identified a SLN in 93 instances, and nodal tumor was seen in 42 patients. Immunohistochemical techniques were used to assess node positivity. Various models of tumor and patient characteristics were studied to predict node positivity. There was no subgroup of patients predicted to have lower than 15% to 20% likelihood of SLN positivity, suggesting that SLN biopsy may be considered for all curative patients with clinically negative lymph nodes and no distant metastases.[22][Level of evidence C2]

Sources: 22 · Level of evidence C2

From 1996 to 2010, another retrospective single-institutional study of 153 patients with localized MCC who underwent SLN biopsy analyzed factors associated with SLN positivity. The best predictors of SLN biopsy positivity were tumor size and lymphovascular invasion.[22,23][Level of evidence C2]

Sources: 22 · 23 · Level of evidence C2

In the absence of adequately powered, prospective, randomized clinical trials, the following questions remain:[4,12,21,24][Level of evidence C2]

Sources: 4 · 12 · 21 · 24 · Level of evidence C2

Should every positive SLN biopsy be followed routinely by completion nodal surgery and/or radiation therapy?

Are outcomes demonstrably improved by routinely adding radiation if lymph node surgery reveals tumor in multiple nodes and/or extracapsular extension and/or lymphovascular invasion?

Should patients with MCCs smaller than 1 cm routinely undergo sentinel lymph node dissection (SLND)?

Should patients with negative or omitted nodal work-up routinely undergo local or local-regional radiation therapy?

Should immunohistochemical staining techniques be used to identify micrometastases in lymph nodes, and is micrometastatic disease in nodes clinically relevant?

Lymph node surgery is primarily used for staging and guiding additional treatment.

Based on a small number of retrospective studies, therapeutic dissection of the regional lymph nodes after a positive SLND appears to minimize, but not totally eliminate, the risk of subsequent regional lymph node recurrence and in-transit metastases.[4,21,24][Level of evidence C2] There are no data from prospective randomized trials demonstrating that definitive regional nodal treatment with surgery improves survival.

Sources: 4 · 21 · 24 · Level of evidence C2

Health professional · Treatment Option Overview for Merkel Cell Carcinoma

Radiation Therapy

Source: Merkel Cell Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

Because of the aggressive nature of MCC, its apparent radiosensitivity, and the high incidence of local and regional recurrences (including in-transit metastases after surgery alone to the primary tumor bed), some clinicians have recommended adjuvant radiation therapy to the primary site and nodal basin. Nodal basin radiation in contiguity with radiation to the primary site has been considered, especially for patients with larger tumors, locally unresectable tumors, close or positive excision margins that cannot be improved by additional surgery, and those with positive regional lymph nodes, especially after SLND (stage II).[10,11,14,15,25][Level of evidence C2] Several small retrospective series have shown that radiation therapy plus adequate surgery improves local-regional control compared with surgery alone,[2,5,26-29] whereas other series did not show the same results.[4,8][Level of evidence C2]

Sources: 10 · 11 · 14 · 15 · 25 · Level of evidence C2 · 2 · 5 · 26 · 29 · 4 · 8 · Level of evidence C2

In the absence of adequately powered, prospective, randomized clinical trials, the following questions remain:[4,8,9,12,21,24,26,30-34][Level of evidence C2]

Sources: 4 · 8 · 9 · 12 · 21 · 24 · 26 · 30 · 34 · Level of evidence C2

Should every positive SLN biopsy be followed routinely by completion nodal surgery and/or radiation therapy?

Are outcomes demonstrably improved by routinely adding radiation only if nodal surgery reveals tumor in multiple lymph nodes and/or extracapsular extension and/or lymphovascular invasion?

Should all or just certain patients with negative or omitted nodal work-up receive local or local-regional radiation routinely?

Because of the small size of these nonrandomized retrospective series, the precise benefit from radiation therapy remains unproven.

When recommended, the radiation dose given has been at least 50 Gy to the surgical bed with margins and to the draining regional lymphatics, delivered in 2 Gy fractions. For patients with unresected tumors or tumors with microscopic evidence of spread beyond resected margins, higher doses of 56 Gy to 65 Gy to the primary site have been recommended.[5,10,11,14,15,27,31,35][Level of evidence C2] These doses have not been studied prospectively in clinical trials.

Sources: 5 · 10 · 11 · 14 · 15 · 27 · 31 · 35 · Level of evidence C2

Local and/or regional control of MCC with radiation therapy alone has been reported in small, highly selected, nonrandomized case series of patients with diverse clinical characteristics.[29,36] Typically, these patients have had inoperable primary tumors and/or nodes or were considered medically inappropriate for surgery.[29,36][Level of evidence C2]

Sources: 29 · 36 · 29 · 36 · Level of evidence C2

Retrospective Surveillance, Epidemiology, and End Results (SEER) Program data suggest that adding radiation therapy to surgery adds survival value, but the conclusions are complicated by incomplete patient data, no protocol for evaluation and treatment, and potential sampling bias.[32] Prospective randomized clinical trials are required to assess whether combining surgery with radiation therapy affects survival.[33,34][Level of evidence C2]

Sources: 32 · 33 · 34 · Level of evidence C2

Health professional · Treatment Option Overview for Merkel Cell Carcinoma

Immunotherapy

Source: Merkel Cell Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

Approximately 70% to 80% of MCC cases in the United States are caused by Merkel cell polyomavirus (MCPyV). Within virus-positive MCCs, the viral oncoproteins (T antigens) are constitutively expressed and promote growth. Furthermore, patients with stimulated immune responses to MCPyV have better disease outcomes, providing a rationale for the use of immunotherapy. Although limited by a lack of randomized trials, several single-agent immune checkpoint inhibitors have shown improved survival and tolerability in patients with advanced MCC, compared with the chemotherapy that was used in historical controls. Therefore, immune checkpoint inhibitors are considered the recommended first-line treatment for most patients. There are ongoing trials to assess the use of immune checkpoint inhibitors in the neoadjuvant and adjuvant setting.

Health professional · Treatment Option Overview for Merkel Cell Carcinoma / Immunotherapy

Avelumab

Source: Merkel Cell Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

Avelumab is a human anti–programmed death ligand-1 (PD-L1) monoclonal antibody.

Evidence (avelumab):

In a phase II trial (JAVELIN Merkel 200 [NCT02155647]), 88 patients with metastatic MCC received avelumab (10 mg/kg intravenously [IV] every 2 weeks). These patients had previously received chemotherapy.[37] Based on the results of this study, the U.S. Food and Drug Administration (FDA) approved avelumab in 2017 for the treatment of patients with metastatic MCC, regardless of previous chemotherapy administration.[37-39]

Sources: JAVELIN Merkel 200 · 37 · 37 · 39

In a phase II trial (JAVELIN Merkel 200 [NCT02155647]), 88 patients with metastatic MCC received avelumab (10 mg/kg intravenously [IV] every 2 weeks). These patients had previously received chemotherapy.[37] Based on the results of this study, the U.S. Food and Drug Administration (FDA) approved avelumab in 2017 for the treatment of patients with metastatic MCC, regardless of previous chemotherapy administration.[37-39]

The objective response rate was 33%, and 11% of patients had a complete response. The median time to response was 6.1 weeks and was irrespective of MCPyV or PD-L1 status. More importantly, responses were durable, with 74% lasting at least 1 year. The median OS was 12.6 months, more than twice the historical median with second-line chemotherapy.

Avelumab was also studied in the first-line setting in a single-arm phase II trial of 116 patients.[40]

Sources: 40

Avelumab was also studied in the first-line setting in a single-arm phase II trial of 116 patients.[40]

After a median follow-up of 21.2 months, 30.2% (95% confidence interval [CI], 22.0%–39.4%) of patients had a durable response (>6 months). The objective response rate was 39.7%, and the median OS was 20.3 months (95% CI, 12.4–not estimable).[40][Level of evidence C3]

Sources: 40 · Level of evidence C3

Exploratory analyses found that responses were higher in patients with PD-L1 expression and in those negative for MCPyV.

Health professional · Treatment Option Overview for Merkel Cell Carcinoma / Immunotherapy

Pembrolizumab

Source: Merkel Cell Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

Pembrolizumab is a humanized IgG4 anti–programmed cell death-1 (PD-1) monoclonal antibody.

Evidence (pembrolizumab):

Pembrolizumab was studied in a phase II trial (NCT02267603) of first-line systemic treatment for patients with unresectable stage IIIB or stage IV MCC. A total of 50 patients received therapy.[41][Level of evidence C3] The FDA approved pembrolizumab in 2018.

Sources: NCT02267603 · 41 · Level of evidence C3

Pembrolizumab was studied in a phase II trial (NCT02267603) of first-line systemic treatment for patients with unresectable stage IIIB or stage IV MCC. A total of 50 patients received therapy.[41][Level of evidence C3] The FDA approved pembrolizumab in 2018.

The objective response rate was 58% (95% CI, 43.2%–71.8%); 30% of patients had a complete response and 28% had a partial response. While the response rate was similar to historical rates with first-line chemotherapy, responses to pembrolizumab were more durable. The median progression-free survival (PFS) was 16.8 months (95% CI, 4.6–43.4), and the 3-year OS rate was 59.4%.

Health professional · Treatment Option Overview for Merkel Cell Carcinoma / Immunotherapy

Retifanlimab

Source: Merkel Cell Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

Retifanlimab is an anti–PD-1 monoclonal antibody.

Evidence (retifanlimab):

Retifanlimab was evaluated in a phase II trial (POD1UM-201 [NCT03599713]), published in abstract form, of 101 patients with previously untreated advanced MCC. Patients received 500mg intravenously (IV) every 4 weeks.[42,43] Based on the results of this trial, the FDA granted accelerated approval to retifanlimab in 2023.

Sources: POD1UM-201 · 42 · 43

Retifanlimab was evaluated in a phase II trial (POD1UM-201 [NCT03599713]), published in abstract form, of 101 patients with previously untreated advanced MCC. Patients received 500mg intravenously (IV) every 4 weeks.[42,43] Based on the results of this trial, the FDA granted accelerated approval to retifanlimab in 2023.

Preliminary results after a median follow up 17.6 months demonstrated a complete response rate of 16.8%, a partial response rate of 38.6%, and an overall response rate of 53.5% (95% CI, 43.3%–63.5%).[42,43][Level of evidence C3]

Sources: 42 · 43 · Level of evidence C3

The median PFS was 12.7 months (95% CI, 7.3–24.9) and the median duration of response was 25.3 months (95% CI, 14.2–not estimable). The median OS was not yet reached.

Health professional · Treatment Option Overview for Merkel Cell Carcinoma / Immunotherapy

Nivolumab

Source: Merkel Cell Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

Nivolumab is an anti–PD-1 monoclonal antibody.

Evidence (nivolumab):

Nivolumab was studied in a phase I/II trial (CheckMate 358 [NCT02488759]), published in abstract form, in patients with virus-associated cancers, including MCC. Patients may have received up to two prior lines of therapy. Patients with metastatic MCC were eligible regardless of MCPyV status or previous chemotherapy.[44,45]Nivolumab is not approved by the FDA for the treatment of MCC.

Sources: CheckMate 358 · 44 · 45

Nivolumab was studied in a phase I/II trial (CheckMate 358 [NCT02488759]), published in abstract form, in patients with virus-associated cancers, including MCC. Patients may have received up to two prior lines of therapy. Patients with metastatic MCC were eligible regardless of MCPyV status or previous chemotherapy.[44,45]Nivolumab is not approved by the FDA for the treatment of MCC.

Data from 25 patients with metastatic disease demonstrated an overall response rate of 60% with a median treatment duration of 15.8 months. Preliminary results reported an ongoing response rate of 87%, with responses in 13 of 15 patients at last follow-up (median follow-up, 6 months).[44,45][Level of evidence C3]

Sources: 44 · 45 · Level of evidence C3

This trial added a second cohort to investigate nivolumab plus ipilimumab (1 mg/kg) in patients with metastatic MCC.

Health professional · Treatment Option Overview for Merkel Cell Carcinoma

Chemotherapy

Source: Merkel Cell Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

A variety of chemotherapy regimens have been used for patients with MCC in the adjuvant, advanced, and recurrent therapy settings.[5,34,46,47] [Level of evidence C2] No phase III clinical trials have been conducted to demonstrate that adjuvant chemotherapy produces improvements in OS. However, some clinicians recommend its use in most cases because of the following factors:

Sources: 5 · 34 · 46 · 47 · Level of evidence C2

A biological analogy is made between MCC and the histologically similar small cell carcinoma of the lung, which is considered a systemic disease.

The risk of metastases and progression is high with MCC.

Good initial clinical response rates have been noted with some chemotherapy regimens.

When possible, patients can be encouraged to participate in clinical trials.

From 1997 to 2001, the Trans-Tasman Radiation Oncology Group performed a phase II evaluation of 53 patients with high-risk, local-regional MCC. High risk was defined as recurrence after initial therapy, involved lymph nodes, primary tumor larger than 1 cm, gross residual disease after surgery, or occult primary tumor with positive lymph nodes. Therapy included local-regional radiation therapy (50 Gy in 25 fractions), synchronous carboplatin (area under the curve [AUC], 4.5), and IV etoposide (89 mg/m2 on days 1–3 in weeks 1, 4, 7, and 10). Surgery was not standardized for either the primary tumor or the lymph nodes, and 12 patients had close margins, positive margins, or gross residual disease. Twenty-eight patients had undissected nodal beds, and the remainder had a variety of nodal surgeries. With a median follow-up of 48 months, the 3-year OS rate was 76%, the rate of local-regional control was 75%, and the rate of distant control was 76%. Radiation reactions in the skin and febrile neutropenia were significant clinical acute toxicities. Because of the heterogeneity of the population and the nonstandardized surgery, it is difficult to infer a clear treatment benefit from the chemotherapy.[48][Level of evidence C1]

Sources: 48 · Level of evidence C1

In a subsequent report, the same investigators evaluated a subset of these protocol patients (n = 40, after excluding patients with unknown primary tumors). These patients were compared with 61 historical controls who received no chemotherapy, were treated at the same institutions, were diagnosed before 1997, and had no routine imaging staging studies. Radiation therapy was given to 50 patients. There was no significant survival benefit seen for chemotherapy patients.[49]

Sources: 49

In a subsequent pilot clinical trial of 18 patients from 2004 to 2006, the same investigators attempted to reduce the skin and hematologic toxicity seen in Study 96-07. Carboplatin (AUC, 2) was administered weekly during radiation therapy beginning on day 1 for a maximum of five doses, followed by three cycles of carboplatin (AUC, 4.5; and IV etoposide 80 mg/m2 on days 1–3 beginning 3 weeks after radiation and repeated every 3 weeks for three cycles). The radiation therapy was similar to that in the earlier trial.[48] Results suggested a decrease in hematologic and skin toxicity.[50]

Sources: 48 · 50

Use of chemotherapy has also been reported in selected patients with locally advanced and metastatic disease. In one retrospective study of 107 patients, 57% of patients with metastatic disease and 69% with locally advanced disease responded to initial chemotherapy. The median OS was 9 months for patients with metastatic disease and 24 months for patients with locally advanced disease. At 3 years, the OS rate was projected to be 17% for those with metastatic disease and 35% for those with locally advanced disease. Toxicity was significant, however, and without clear benefit, particularly in older patients.[51][Level of evidence C2]

Sources: 51 · Level of evidence C2

Health professional · Treatment Option Overview for Merkel Cell Carcinoma

Follow-Up

Source: Merkel Cell Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

The most appropriate follow-up techniques and frequency for patients treated for MCC have not been prospectively studied. Because of the propensity for local and regional recurrence, clinicians should perform at least a thorough physical examination of the site of initial disease and the regional lymph nodes. Imaging studies may be ordered to evaluate signs and symptoms of concern, or they may be performed to identify distant metastases early. However, there are no data suggesting that early detection and treatment of new distant metastases results in improved survival.

In one series of 237 patients presenting with local or regional disease, the median time-to-recurrence was 9 months (range, 2–70 months). Ninety-one percent of recurrences occurred within 2 years of diagnosis.[4] It has been suggested that the intensity of follow-up can be gradually diminished after 2 to 3 years because most recurrences are likely to have already occurred.[4]

Sources: 4 · 4

Health professional

Treatment of Stage I and II Merkel Cell Carcinoma

Source: Merkel Cell Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

Stage I and II Merkel cell carcinoma (MCC) include patients with local disease only.

Excision with 1 cm to 2 cm margins and radiation therapy are the mainstays of management for primary MCC tumors. Adjuvant radiation therapy to the primary tumor site is often recommended. However, the morbidity of radiation may be avoided and low local recurrence rates maintained, as shown in a subset of patients with small low-risk lesions (i.e., tumors <2 cm without other adverse prognostic factors).[1]

Sources: 1

Because of the risk of occult nodal disease, sentinel lymph node (SLN) biopsy is recommended for patients without clinically detectable metastatic disease.[2] Any size of metastatic deposit is currently considered positive with regard to regional lymph node (N) staging; therefore, immunohistochemistry is routinely used to improve detection of micrometastases in SLN.[3,4]

Sources: 2 · 3 · 4

Health professional · Treatment of Stage I and II Merkel Cell Carcinoma

Treatment Options for Stage I and II Merkel Cell Carcinoma

Source: Merkel Cell Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

Treatment options for stage I and stage II MCC include:

Sources: stage I · stage II MCC

Margin-negative local excision, attempting to maintain function.

Surgical nodal evaluation, typically by SLN procedure initially, may be considered for patients with significant risk of nodal disease. Completion of the nodal dissection may be considered if positive lymph nodes are found, which would upstage the patient's cancer to stage III.

Local radiation therapy may be considered if there is concern about the primary tumor excision margins. Regional radiation therapy may be considered if the nodal staging procedure is incomplete or omitted. For sites where the location of primary regional lymph nodes may be uncertain (e.g., mid-back), regional-node field selection is problematic.

Enrollment in clinical trials is encouraged.

Health professional

Treatment of Stage III Merkel Cell Carcinoma

Source: Merkel Cell Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

Stage III Merkel cell carcinoma (MCC) includes patients with nodal disease.

Health professional · Treatment of Stage III Merkel Cell Carcinoma

Treatment Options for Stage III Merkel Cell Carcinoma

Source: Merkel Cell Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

Treatment options for stage III MCC include:

Sources: stage III MCC

Margin-negative local excision, attempting to maintain function.

Sentinel lymph node procedure, possibly followed by more definitive regional node surgery if positive node(s) are found.

Local and regional lymph node radiation, especially if there is concern about the adequacy of the primary tumor excision margin or the risk of local-regional recurrence following the nodal surgery (e.g., multiple primary nodes, extracapsular extension, lymphovascular invasion, and evidence of in-transit metastases).

Systemic chemotherapy and immunotherapy have been given to patients with the highest risk of recurrence, but existing data have not proven a clinical survival benefit.

Enrollment in clinical trials is encouraged.

Health professional

Treatment of Stage IV Merkel Cell Carcinoma

Source: Merkel Cell Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

Stage IV Merkel cell carcinoma (MCC) includes patients with distant metastases.

Single-agent immunotherapy is the preferred initial systemic therapy for patients with metastatic disease. Chemotherapy may be considered for patients with stage IV disease who have a good performance status and are either ineligible for or have disease progression while receiving immunotherapy. Although responses have been seen with various regimens, evidence is lacking that chemotherapy results in permanent disease control or long-term survival.

If chemotherapy is not considered an appropriate option, patients with stage IV disease may consider surgery and/or radiation therapy for local or regional palliation.

Health professional · Treatment of Stage IV Merkel Cell Carcinoma

Treatment Options for Stage IV Merkel Cell Carcinoma

Source: Merkel Cell Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

Treatment options for stage IV MCC include:

Sources: stage IV MCC

Single-agent immunotherapy.

Palliation with chemotherapy and/or surgery and/or radiation therapy as clinically appropriate.

Enrollment in clinical trials is strongly encouraged.

Health professional

Treatment of Recurrent Merkel Cell Carcinoma

Source: Merkel Cell Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

Merkel cell carcinoma (MCC) is a rare tumor. Recommendations and outcomes of various treatments for patients with MCC are included in many large case series [1-3][Level of evidence C2] and several single-arm phase II clinical trials.[4][Level of evidence C1] Treatment is usually individualized based on patient preference and the specifics of each case. Patients should strongly consider enrolling in clinical trials.

Sources: 1 · 3 · Level of evidence C2 · 4 · Level of evidence C1

Health professional · Treatment of Recurrent Merkel Cell Carcinoma

Treatment Options for Recurrent Merkel Cell Carcinoma

Source: Merkel Cell Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

Health professional · Treatment of Recurrent Merkel Cell Carcinoma / Treatment Options for Recurrent Merkel Cell Carcinoma

Local recurrence

Source: Merkel Cell Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

Treatment options for patients with local recurrence include wider local surgery if possible, followed by radiation therapy, if not previously given.

Regional lymph node dissection (RLND) can also be considered if regional draining nodes have not been previously removed.

Because of the poor prognosis after recurrence, systemic therapy can also be considered, although there is no evidence that it improves survival.

Health professional · Treatment of Recurrent Merkel Cell Carcinoma / Treatment Options for Recurrent Merkel Cell Carcinoma

Nodal recurrence

Source: Merkel Cell Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

Treatment options for patients with only regional nodal recurrence include RLND and adjuvant radiation therapy if the regional draining nodes have not been previously treated. Because of the poor prognosis after recurrence, consideration can also be given to systemic therapy, although there is no evidence that it improves survival.

Health professional · Treatment of Recurrent Merkel Cell Carcinoma / Treatment Options for Recurrent Merkel Cell Carcinoma

Distant recurrence

Source: Merkel Cell Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

For patients with distant disease, several single-agent immunotherapies have elicited durable responses and are the recommended first-line systemic therapy option for most patients. Among these agents, avelumab and pembrolizumab have longer-term follow-up data published. These agents are approved by the U.S. Food and Drug Administration (FDA).[5-7][Level of evidence C3] Retifanlimab has also received accelerated approval from the FDA, pending further follow-up.[8][Level of evidence C3]

Sources: 5 · 7 · Level of evidence C3 · 8 · Level of evidence C3

Chemotherapy is an option for patients who are either ineligible for or have disease progression while receiving immunotherapy, or in select patients who may benefit from a more rapid response.[1-4,9,10][Level of evidence C2] Although responses with chemotherapy have been reported in selected patients with locally advanced and metastatic disease, toxicity has been significant and durability is limited. When appropriate, radiation therapy and/or surgery may be offered as palliation to sites of recurrence, particularly if chemotherapy is not considered an option.

Sources: 1 · 4 · 9 · 10 · Level of evidence C2

For patients · General Information About Merkel Cell Carcinoma

Certain factors affect prognosis (chance of recovery) and treatment options.

Source: Merkel Cell Carcinoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

The prognosis and treatment options depend on:

the stage of the cancer (the size of the tumor and whether it has spread to the lymph nodes or other parts of the body)

where the cancer is in the body

whether the cancer has just been diagnosed or has recurred (come back)

Sources: recurred

the person's age and general health

Prognosis also depends on how deeply the tumor has grown into the skin.

For patients · Stages of Merkel Cell Carcinoma

It is common for Merkel cell carcinoma to recur (come back) after it has been treated.

Source: Merkel Cell Carcinoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

Recurrent Merkel cell carcinoma is cancer that has come back after it has been treated. If Merkel cell carcinoma comes back, it may come back in the skin, lymph nodes, or other parts of the body. Tests will be done to help determine where the cancer has returned. The type of treatment for recurrent Merkel cell carcinoma will depend on where it has come back.

Sources: lymph nodes

Learn more in Recurrent Cancer: When Cancer Comes Back.

Sources: Recurrent Cancer: When Cancer Comes Back

For patients

Treatment Option Overview

Source: Merkel Cell Carcinoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

For patients · Treatment Option Overview

Key Points

Source: Merkel Cell Carcinoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

There are different types of treatment for people with Merkel cell carcinoma.

The following types of treatment are used:

The following types of treatment are used:

Surgery

Radiation therapy

Chemotherapy

Immunotherapy

New types of treatment are being tested in clinical trials.

Treatment for Merkel cell carcinoma may cause side effects.

Follow-up care may be needed.

For patients · Treatment Option Overview

There are different types of treatment for people with Merkel cell carcinoma.

Source: Merkel Cell Carcinoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

Different types of treatments are available for Merkel cell carcinoma. You and your cancer care team will work together to decide your treatment plan, which may include more than one type of treatment. Many factors will be considered, such as the stage of the cancer, your overall health, and your preferences. Your plan will include information about your cancer, the goals of treatment, your treatment options and the possible side effects, and the expected length of treatment.

Talking with your cancer care team before treatment begins about what to expect will be helpful. You’ll want to learn what you need to do before treatment begins, how you’ll feel while going through it, and what kind of help you will need. To learn more, visit Questions to Ask Your Doctor About Treatment.

Sources: Questions to Ask Your Doctor About Treatment

For patients · Treatment Option Overview

The following types of treatment are used:

Source: Merkel Cell Carcinoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

For patients · Treatment Option Overview / The following types of treatment are used:

Surgery

Source: Merkel Cell Carcinoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

One or more of the following surgical procedures may be used to treat Merkel cell carcinoma:

Wide local excision: The cancer is cut from the skin along with some of the tissue around it. A sentinel lymph node biopsy may be done during the wide local excision procedure. If there is cancer in the lymph nodes, a lymph node dissection also may be done.

Sources: Wide local excision · sentinel lymph node biopsy · lymph nodes · lymph node dissection

Lymph node dissection: A surgical procedure in which the lymph nodes are removed and a sample of tissue is checked under a microscope for signs of cancer. For a regional lymph node dissection, some of the lymph nodes in the tumor area are removed; for a radical lymph node dissection, most or all of the lymph nodes in the tumor area are removed. This procedure is also called lymphadenectomy.

Sources: regional lymph node dissection · radical lymph node dissection

After the doctor removes all the cancer that can be seen at the time of the surgery, some patients may be given chemotherapy or radiation therapy after surgery to kill any cancer cells that are left. Treatment given after the surgery, to lower the risk that the cancer will come back, is called adjuvant therapy.

Sources: chemotherapy · radiation therapy

For patients · Treatment Option Overview / The following types of treatment are used:

Radiation therapy

Source: Merkel Cell Carcinoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

Radiation therapy uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer. It is used to treat Merkel cell carcinoma and may also be used as palliative therapy to relieve symptoms and improve quality of life.

Sources: x-rays · radiation · External radiation therapy · palliative therapy · symptoms · quality of life

Learn more about Radiation Therapy to Treat Cancer and Radiation Therapy Side Effects.

Sources: Radiation Therapy to Treat Cancer · Radiation Therapy Side Effects

For patients · Treatment Option Overview / The following types of treatment are used:

Chemotherapy

Source: Merkel Cell Carcinoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

Chemotherapy (also called chemo) uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping the cells from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy).

Sources: injected · systemic chemotherapy

Learn more about how chemotherapy works, how it is given, common side effects, and more at Chemotherapy to Treat Cancer and Chemotherapy and You: Support for People With Cancer.

Sources: Chemotherapy to Treat Cancer · Chemotherapy and You: Support for People With Cancer

For patients · Treatment Option Overview / The following types of treatment are used:

Immunotherapy

Source: Merkel Cell Carcinoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

Immunotherapy helps a person's immune system fight cancer.

Sources: immune system

Immunotherapy drugs used to treat Merkel cell carcinoma include:

avelumab

Sources: avelumab

pembrolizumab

Sources: pembrolizumab

retifanlimab

Sources: retifanlimab

Learn more about Immunotherapy to Treat Cancer.

Sources: Immunotherapy to Treat Cancer

For patients · Treatment Option Overview

New types of treatment are being tested in clinical trials.

Source: Merkel Cell Carcinoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

For some people, joining a clinical trial may be an option. There are different types of clinical trials for people with cancer. For example, a treatment trial tests new treatments or new ways of using current treatments. Supportive care and palliative care trials look at ways to improve quality of life, especially for those who have side effects from cancer and its treatment.

You can use the clinical trial search to find NCI-supported cancer clinical trials accepting participants. The search allows you to filter trials based on the type of cancer, your age, and where the trials are being done. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.

Sources: clinical trial search · ClinicalTrials.gov

Learn more about clinical trials, including how to find and join one, at Clinical Trials Information for Patients and Caregivers.

Sources: Clinical Trials Information for Patients and Caregivers

For patients · Treatment Option Overview

Treatment for Merkel cell carcinoma may cause side effects.

Source: Merkel Cell Carcinoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

For information about side effects caused by treatment for cancer, visit our Side Effects page.

Sources: side effects · Side Effects

For patients · Treatment Option Overview

Follow-up care may be needed.

Source: Merkel Cell Carcinoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.

Sources: diagnose · stage

Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).

For patients

Treatment of Stage I and Stage II Merkel Cell Carcinoma

Source: Merkel Cell Carcinoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

Treatment of stage I and stage II Merkel cell carcinoma may include:

Sources: stage I · stage II

surgery to remove the tumor, such as wide local excision with or without lymph node dissection

Sources: wide local excision · lymph node dissection

radiation therapy after surgery

Sources: radiation therapy

Learn more about these treatments in the Treatment Option Overview.

Sources: Treatment Option Overview

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Stage III Merkel Cell Carcinoma

Source: Merkel Cell Carcinoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

Treatment of stage III Merkel cell carcinoma may include:

Sources: stage III

wide local excision with or without lymph node dissection

Sources: wide local excision · lymph node dissection

radiation therapy

Sources: radiation therapy

chemotherapy and immunotherapy with an immune checkpoint inhibitor (pembrolizumab), for tumors that cannot be removed by surgery

Sources: chemotherapy · immunotherapy · immune checkpoint inhibitor · pembrolizumab

Learn more about these treatments in the Treatment Option Overview.

Sources: Treatment Option Overview

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Stage IV Merkel Cell Carcinoma

Source: Merkel Cell Carcinoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

Treatment of stage IV Merkel cell carcinoma may include:

Sources: stage IV

immunotherapy with an immune checkpoint inhibitor (avelumab, pembrolizumab, or retifanlimab)

Sources: immunotherapy · immune checkpoint inhibitor · avelumab · pembrolizumab · retifanlimab

chemotherapy, surgery, or radiation therapy as palliative treatment to relieve symptoms and improve quality of life

Sources: chemotherapy · radiation therapy · palliative treatment · symptoms · quality of life

Learn more about these treatments in the Treatment Option Overview.

Sources: Treatment Option Overview

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Recurrent Merkel Cell Carcinoma

Source: Merkel Cell Carcinoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

Treatment of recurrent Merkel cell carcinoma may include:

Sources: recurrent

wide local excision to remove a larger area of tissue than was removed in earlier surgery with or without lymph node dissection

Sources: wide local excision · lymph node dissection

radiation therapy after surgery

Sources: radiation therapy

chemotherapy

Sources: chemotherapy

immunotherapy with an immune checkpoint inhibitor (avelumab, pembrolizumab, or retifanlimab)

Sources: immunotherapy · immune checkpoint inhibitor · avelumab · pembrolizumab · retifanlimab

radiation therapy and/or surgery as palliative treatment to relieve symptoms and improve quality of life

Sources: palliative treatment · symptoms · quality of life

Learn more about these treatments in the Treatment Option Overview.

Sources: Treatment Option Overview

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

Studies

Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)

NCT02155647 · COMPLETED · phase2

Carcinoma, Merkel Cell

ClinicalTrials.gov record

Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer

NCT02267603 · COMPLETED · phase2

Recurrent Merkel Cell Carcinoma, Stage III Merkel Cell Carcinoma AJCC v7, Stage IIIA Merkel Cell Carcinoma AJCC v7, Stage IIIB Merkel Cell Carcinoma AJCC v7, Stage IV Merkel...

ClinicalTrials.gov record

An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors

NCT02488759 · COMPLETED · phase1, phase2

Various Advanced Cancer

ClinicalTrials.gov record

A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)

NCT03599713 · COMPLETED · phase2

Metastatic Merkel Cell Carcinoma

ClinicalTrials.gov record

Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)

NCT03783078 · COMPLETED · phase3

Merkel Cell Carcinoma

ClinicalTrials.gov record

Disease and treatment settings

Bavencio: metastatic Merkel Cell Carcinoma

Disease and treatment setting

Treatment of adults and pediatrics patients 12 years and older with metastatic merkel cell carcinoma (MCC)

BAVENCIO: metastatic Merkel Cell Carcinoma with PD-L1 stated without a specific alteration

Disease and treatment setting

1 INDICATIONS AND USAGE BAVENCIO is a programmed death ligand-1 (PD-L1) blocking antibody indicated for: Merkel Cell Carcinoma (MCC) Adults and pediatric patients 12 years and older with metastatic MCC.

KEYTRUDA QLEX: metastatic Merkel Cell Carcinoma

Disease and treatment setting

1.13 Merkel Cell Carcinoma KEYTRUDA QLEX is indicated for the treatment of adult and pediatric patients 12 years and older with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).

Keytruda: metastatic Merkel Cell Carcinoma

Disease and treatment setting

Treatment of adults and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC)

Merkel Cell Carcinoma

Disease and treatment setting

Merkel Cell Carcinoma

recurrent Merkel Cell Carcinoma

Disease and treatment setting

Treatment of Recurrent Merkel Cell Carcinoma

Stage I Merkel Cell Carcinoma

Disease and treatment setting

Treatment of Stage I and II Merkel Cell Carcinoma

Stage III Merkel Cell Carcinoma

Disease and treatment setting

Treatment of Stage III Merkel Cell Carcinoma

Stage IV Merkel Cell Carcinoma

Disease and treatment setting

Treatment of Stage IV Merkel Cell Carcinoma

Zynyz: metastatic Merkel Cell Carcinoma

Disease and treatment setting

Adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC)

Drug labels

BAVENCIO

Label date 2026-08-25

BAVENCIO is a programmed death ligand-1 (PD-L1) blocking antibody indicated for: Merkel Cell Carcinoma (MCC) Adults and pediatric patients 12 years and older with metastatic MCC. ( 1.1 , 14.1 ) Urothelial Carcinoma (UC) Maintenance...

DailyMed label

ZYNYZ

Label date 2026-05-18

ZYNYZ is a programmed death receptor-1 (PD-1)–blocking antibody indicated: Squamous Cell Carcinoma of the Anal Canal (SCAC) in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with inoperable...

DailyMed label